Possible value of H2-receptor agonists for treatment of catecholamine-insensitive congestive heart failure.
D000262:Adenylyl Cyclases / Q000032:analysis; D000328:Adult; D000368:Aged; D002395:Catecholamines / Q000494:pharmacology*; D004082:Dihydroalprenolol / Q000378:metabolism; D004280:Dobutamine / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006349:Heart Valve Diseases / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D017446:Impromidine; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D011968:Receptors, Histamine / Q000187:drug effects*; D011970:Receptors, Histamine H2 / Q000187:drug effects*
D002395:Catecholamines; D007093:Imidazoles; D011943:Receptors, Adrenergic, beta; D011968:Receptors, Histamine; D011970:Receptors, Histamine H2; D004280:Dobutamine; D004082:Dihydroalprenolol; D017446:Impromidine; D000262:Adenylyl Cyclases